In this video, Dr. Shiva Ayyadurai provides a modern theory of the immune system – an exemplar systems architecture resulting from CytoSolve – a platform for precision and personalized medicine enabling the development of engineering systems architectures and mechanistic models of large-scale biological systems, diseases, and bio-molecular processes. As the multi-trillion dollar pharmaceutical industry heads into peril with year-over-year increases in R&D expenditure without concomitant increases in FDA allowances for new molecules alongside escalating healthcare costs, CytoSolve offers a decentralized collaboratory or scalable integration of molecular pathway models for discovery of multi-combination therapeutics, safer, faster and cheaper. Dr. Ayyadurai also shares his journey to MIT and commercial successes of CytoSolve including FDA allowance for a multicombination therapeutic for pancreatic cancer; use of CytoSolve by global pharmaceutical companies such as Pfizer and emerging biotech’s such as Alnylam for accelerating drug development; discovery of nearly twenty new therapeutics and patent filings cross diverse indications; development of disease models for both major diseases such as Alzheimer’s and rare diseases in orphan drug domains such as Neuromyelitis Optica (NMO) and Hereditary Angioedema (HAE). He also speaks about the innovative research and development partnerships that CytoSolve’s decentralized collaboratory framework has afforded for foundations, universities, and research centers. Learn more about CytoSolve at: https://cytosolve.com/ - Systems Health - 508DrShiva

Dr. Shiva Ayyadurai Delivers Prestige Lecture at NSF Science & Technology Center, Purdue University

Dr. Shiva Ayyadurai Delivers Prestige Lecture at NSF Science & Technology Center, Purdue University

vashiva@vashiva.com Photo
vashiva@vashiva.com
4 years
4.4K Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 1
Category:
Systems Health
Description:
In this video, Dr. Shiva Ayyadurai provides a modern theory of the immune system – an exemplar systems architecture resulting from CytoSolve – a platform for precision and personalized medicine enabling the development of engineering systems architectures and mechanistic models of large-scale biological systems, diseases, and bio-molecular processes. As the multi-trillion dollar pharmaceutical industry heads into peril with year-over-year increases in R&D expenditure without concomitant increases in FDA allowances for new molecules alongside escalating healthcare costs, CytoSolve offers a decentralized collaboratory or scalable integration of molecular pathway models for discovery of multi-combination therapeutics, safer, faster and cheaper. Dr. Ayyadurai also shares his journey to MIT and commercial successes of CytoSolve including FDA allowance for a multicombination therapeutic for pancreatic cancer; use of CytoSolve by global pharmaceutical companies such as Pfizer and emerging biotech’s such as Alnylam for accelerating drug development; discovery of nearly twenty new therapeutics and patent filings cross diverse indications; development of disease models for both major diseases such as Alzheimer’s and rare diseases in orphan drug domains such as Neuromyelitis Optica (NMO) and Hereditary Angioedema (HAE). He also speaks about the innovative research and development partnerships that CytoSolve’s decentralized collaboratory framework has afforded for foundations, universities, and research centers. Learn more about CytoSolve at: https://cytosolve.com/

Comments:

Comment
Up Next Autoplay